Travere Therapeutics, Inc. SEC filings TVTX
Travere Therapeutics, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Oct 8, 2015. Its latest annual report, Form ARS, was filed on Apr 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 2, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Jun 17, 2026 | — |
| 424B5 | Prospectus supplement | May 7, 2026 | — |
| FWP | Free writing prospectus | May 7, 2026 | — |
| 424B5 | Prospectus supplement | May 5, 2026 | — |
| S-8 | Employee stock plan registration | Jun 17, 2025 | — |
| 424B5 | Prospectus supplement | Nov 8, 2024 | — |
| 424B5 | Prospectus supplement | Nov 7, 2024 | — |
| 424B5 | Prospectus supplement | Oct 31, 2024 | — |
| S-3ASR | Automatic shelf registration | Aug 1, 2024 | — |
| S-8 | Employee stock plan registration | Jun 14, 2024 | — |
| S-8 | Employee stock plan registration | Aug 3, 2023 | — |
| 424B5 | Prospectus supplement | Mar 1, 2023 | — |
| FWP | Free writing prospectus | Mar 1, 2023 | — |
| 424B5 | Prospectus supplement | Feb 27, 2023 | — |
| S-8 | Employee stock plan registration | Aug 18, 2022 | — |
| 424B5 | Prospectus supplement | Mar 9, 2022 | — |
| FWP | Free writing prospectus | Mar 9, 2022 | — |
| FWP | Free writing prospectus | Mar 9, 2022 | — |
| 424B5 | Prospectus supplement | Mar 8, 2022 | — |
| S-3ASR | Automatic shelf registration | Sep 3, 2021 | — |
| S-8 | Employee stock plan registration | Jul 29, 2021 | — |
| 424B5 | Prospectus supplement | Feb 12, 2021 | — |
| 424B5 | Prospectus supplement | Feb 10, 2021 | — |
| S-8 | Employee stock plan registration | Jul 31, 2020 | — |
| 424B5 | Prospectus supplement | Jun 9, 2020 | — |
| 424B5 | Prospectus supplement | Jun 8, 2020 | — |
| 424B5 | Prospectus supplement | Feb 24, 2020 | — |
| S-8 | Employee stock plan registration | Jul 26, 2019 | — |
| 424B5 | Prospectus supplement | Sep 6, 2018 | — |
| FWP | Free writing prospectus | Sep 6, 2018 | — |
| 424B5 | Prospectus supplement | Sep 4, 2018 | — |
| S-3ASR | Automatic shelf registration | Sep 4, 2018 | — |
| S-8 | Employee stock plan registration | May 11, 2018 | — |
| S-8 | Employee stock plan registration | Jun 8, 2017 | — |
| S-8 | Employee stock plan registration | Sep 13, 2016 | — |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TVTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1438533
- Former names
- Retrophin, Inc. (until Nov 13, 2020); Desert Gateway, Inc. (until Feb 19, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.